Table 4 Summary of adverse events causally related to treatment with AZD9164
AEs assessed as causally-related to AZD9164 | |||||
|---|---|---|---|---|---|
Placebo | AZD9164 | ||||
GMAD, healthy subjects | n = 9 | 400 μg | 1000 μg | 2800 μg | Total (%) |
n = 6 | n = 6 | n = 6 | n = 27 | ||
Dry mouth | 0 | 1 (16.7) | 1 (3.7) | ||
Throat irritation | 0 | 3 (50.0) | 3 (11.1) | ||
Cough | 0 | 2 (33.3) | 2 (7.4) | ||
Flushing | 0 | 1 (16.7) | 1 (3.7) | ||
JMAD, healthy subjects | n = 6 | 400 μg | 1000 μg | Total (%) | |
n = 6 | n = 6 | n = 18 | |||
Rash | 0 | 1 (16.7) | 1 (5.6) | ||
Headache | 0 | 1 (16.7) | 1 (5.6) | ||
Cough | 0 | 1 (16.7) | 1 (16.7) | 2 (11.1) | |
Upper respiratory tract infection | 0 | 1 (16.7) | 0 | 1 (5.6) | |
Respiratory tract irritation | 0 | 1 (16.7) | 1 (5.6) | ||
Epistaxis | 0 | 1 (16.7) | 1 (5.6) | ||
Nasal mucosal disorder | 0 | 1 (16.7) | 1 (5.6) | ||
GMAD, COPD patients | n = 1 | n = 3 | n = 4 | ||
Dry mouth | 0 | 1 (33.3) | 1 (25.0) | ||
Palpitations | 0 | 1 (33.3) | 1 (25.0) | ||
Anxiety | 0 | 1 (33.3) | 1 (25.0) | ||
Dyspnoea | 0 | 2 (66.6) | 2 (50.0) | ||
Cough | 0 | 1 (33.3) | 1 (25.0) | ||
Haematoma | 0 | 1 (33.3) | 1 (25.0) | ||
Fatigue | 0 | 1 (33.3) | 1 (25.0) | ||